Role of Circulating Fibroblast Growth Factor 23 in the Development of Secondary Hyperparathyroidism
- 19 July 2005
- journal article
- review article
- Published by Wiley in Therapeutic Apheresis and Dialysis
- Vol. 9 (4), 328-330
- https://doi.org/10.1111/j.1744-9987.2005.00291.x
Abstract
It would be useful to predict the future development of hyperparathyroidism before treatment with active vitamin D agents. Fibroblast growth factor 23 (FGF23) is a newly identified humoral phosphaturic factor. Positive correlation was found between parathyroid function and serum FGF23 levels in dialysis patients. Interestingly, FGF23 levels showed even better correlation with intact parathyroid hormone (iPTH) levels 2 years after the sample collection for the FGF23 measurement. In long‐term dialysis patients with mild secondary hyperparathyroidism, serum FGF23 level was the best screening test to discriminate patients with future advanced secondary hyperparathyroidism within 2 years. In dialysis patients with advanced secondary hyperparathyroidism, the pretreatment FGF23 levels, as well as iPTH levels, significantly affected the outcome of calcitriol therapy. Thus, the measurement of serum FGF23 level is a promising laboratory examination to predict the future development of secondary hyperparathyroidism. The mechanism of this phenomenon, however, remains to be revealed.Keywords
This publication has 15 references indexed in Scilit:
- Serum fibroblast growth factor-23 levels predict the future refractory hyperparathyroidism in dialysis patientsKidney International, 2005
- Pretreatment serum FGF-23 levels predict the efficacy of calcitriol therapy in dialysis patientsKidney International, 2005
- Possible involvement of circulating fibroblast growth factor 23 in the development of secondary hyperparathyroidism associated with renal insufficiencyAmerican Journal of Kidney Diseases, 2004
- FGF-23 in patients with end-stage renal disease on hemodialysisKidney International, 2004
- The treatment of glomerular disease--a compromise between the standard and the individual approachNephrology Dialysis Transplantation, 2003
- FGF23, PHEX, and MEPE regulation of phosphate homeostasis and skeletal mineralizationAmerican Journal of Physiology-Endocrinology and Metabolism, 2003
- Evaluation of blood supply to the parathyroid glands in secondary hyperparathyroidism compared with histopathologyNephrology Dialysis Transplantation, 2003
- Identification of a Novel Fibroblast Growth Factor, FGF-23, Preferentially Expressed in the Ventrolateral Thalamic Nucleus of the BrainBiochemical and Biophysical Research Communications, 2000
- Are we mismanaging calcium and phosphate metabolism in renal failure?American Journal of Kidney Diseases, 1997
- Decreased 1,25-dihydroxyvitamin D3 receptor density is associated with a more severe form of parathyroid hyperplasia in chronic uremic patients.JCI Insight, 1993